Skip to main content
SpringerLink
Log in

Pathophysiology and Management of Heart Failure

  • Chapter
Contemporary Concepts in Cardiology

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 217))

Abstract

Heart failure affects an estimated 1% of the population in the western world and results in an average mortality rate of 10% at 1 year and 50% after 5 years 1. The incidence of heart failure rises substantially beyond age 65, therefore, the prevalence of this condition is likely to increase as the population ages. In fact, in the elderly the incidence approaches 1 in 10 2. Consequently, heart failure places a significant economic burden on society 1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agenet for Health Care Policy and Research (AHCPR) panel for Heart failure 1995.

    Google Scholar 

  2. Taylor SH. The heart failure syndrome-from prevention to treatment. Eur Heart J 1995: 16: 1.

    Article  Google Scholar 

  3. Packer M. Pathophysiology of chronic heart failure. Lancet 1992: 340: 88.

    Article  PubMed  CAS  Google Scholar 

  4. Kentish JC, et al. Comparison between the sarcomere length-force relations of intact and skinned trabeculae from rat right ventricle. Circ Res 1986: 58: 755.

    Article  PubMed  CAS  Google Scholar 

  5. Nadal-Ginard B, et al. Molecular basis of cardiac performance: Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989: 84: 1693.

    Article  PubMed  CAS  Google Scholar 

  6. Hirsch AT, Dzau VJ, Creager MA. Baroreceptors function is congestive heart failure: effect on neurohormonal activation and regional vascular resistance. Circulation 1987: 75 (suppl IV): 36.

    Google Scholar 

  7. Floras JS. Sympathoinhibitory effect of atrial natriuetic factor in normal humans. Circulation 1990: 81: 1860.

    Article  PubMed  CAS  Google Scholar 

  8. Cody RJ, et al. Atrial Natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986: 78: 1362.

    Article  PubMed  CAS  Google Scholar 

  9. Abassi Z, et al. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. Am J Physiol 1990: 259: R84.

    PubMed  CAS  Google Scholar 

  10. Kimura K, et al. Effects of atrial natiuretic peptide on renal arterioles: morphologic analysis using microvaswculr cells. Am J Physiol 1990: 259: F939.

    Google Scholar 

  11. Moe GW, et al. Response of atrial natriuretic factor to acute and chronic increases of atrial pressure in experimental heart failure in dogs: role of changes in heart rate, atrial dimensions, and cardiac tissue concentration. Circulation 1991: 83: 1780.

    Article  PubMed  CAS  Google Scholar 

  12. Hirooka Y, et al. Attenuated forearm vasodilative response to intra-arterial arterial natriuretic peptide in heart failure. Circulation 1990: 82: 147.

    Article  PubMed  CAS  Google Scholar 

  13. Margulies KB, Hildebrand FL, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation 1990: 82: 2226.

    Article  PubMed  CAS  Google Scholar 

  14. Burkart F. Rationale for current drug treatment. Eur Heart J 1995: 16F: 2.

    Article  Google Scholar 

  15. Pitt B, et al. The effect of treatment on survival in congestive heart failure. Clinical Cardiology 1992: 15: 323.

    Article  PubMed  CAS  Google Scholar 

  16. Neumann J, et al. Increase in myocardial Gi-proteins in heart failure. Lancet 1988: 11: 936.

    Article  Google Scholar 

  17. Horn EM, et al. Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting-enzyme-inhibitor therapy. Circulation 1988: 78: 1373.

    Article  PubMed  CAS  Google Scholar 

  18. Eiskjaer H, et al. Mechanisms of sodium retention in heart failure: relation to the renin-angiotensin-aldosterone system. Am J Physiol 1991: 260: F883.

    PubMed  CAS  Google Scholar 

  19. Francis GS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunstion with and without congestive heart failure. A substudy of the studies of left ventricular dysfunstion (SOLVD). Circulation 1990: 82: 1724.

    Article  PubMed  CAS  Google Scholar 

  20. Pettersson A, Hedner J, Hedner T. Renal interaction between the sympathetic and ANP in rats with chronic ischemic heart failure. Acta Physiol Scand 1989: 135: 487.

    Article  PubMed  CAS  Google Scholar 

  21. Ferrari R, Corti A, Bachetti T. Tumor necrosis factor alpha in heart failure. Heart Failure 1995: 11: 142.

    Google Scholar 

  22. McMurray J, et al. Increased concentrationsof tumor necrosis factor in“cachectic”patients with severe chronic heart failure. Br Heart J 1991: 66: 356.

    Article  PubMed  CAS  Google Scholar 

  23. Riegger GA. Lessons from recent randomized controlled trials for the management of congestive heart failure. Am Journal Cardiol 1993: 71: E38

    Article  Google Scholar 

  24. Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfuction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992: 327: 669.

    Article  PubMed  CAS  Google Scholar 

  25. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987: 316: 1429.

    Article  Google Scholar 

  26. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left-ventricular ejection fractions. N Engl J Med 1992: 327: 685.

    Article  Google Scholar 

  27. Lewis GR. Comparison of lisinopril versus placebo for congestive heart failure. Am J Cardiol 1989: 63: 12D.

    Article  PubMed  CAS  Google Scholar 

  28. Harlan WR, et al. Chronic congestive heart failure in coronary artery disease: clinical critera. Ann Intern Med 1977: 86: 133.

    PubMed  CAS  Google Scholar 

  29. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure. N Engl J Med 1991: 325: 293.

    Article  Google Scholar 

  30. Packer M. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995: 16: F4.

    Article  Google Scholar 

  31. Pfeffer MA, et al. Effect of captopril on progressive ventricular dialtation after anterior myocardial infarction. N Engl J Med 1988: 319: 80.

    Article  PubMed  CAS  Google Scholar 

  32. Tan LB, et al. Cardiac myocyte necrosis induced by angiotensin II. Circulation Research 1991: 69: 1185.

    Article  PubMed  CAS  Google Scholar 

  33. Greenberg B, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography sudstudy. Circulation 1995: 91: 2573.

    Article  PubMed  CAS  Google Scholar 

  34. Benedict CR, et al. Effect of long-term enelapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 1995: 75: 115.

    Article  Google Scholar 

  35. The TRACE Study Group. The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characterists of the screened population. Am J Cardiol 1994: 73: C44.

    Article  Google Scholar 

  36. Ball SG, Hall AS, Murray GD. ACE inhibition, atherosclerosis and myocardial infarction-The Acute Infarction Ramipril Efficacy Study (AIRE). Eur Heart J 1994: 15: B20.

    Article  Google Scholar 

  37. Swedberg K, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992: 327: 678.

    Article  PubMed  CAS  Google Scholar 

  38. Ambrosiano E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and mobibidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995: 332: 80.

    Article  Google Scholar 

  39. Packer M, et al. Withdrawal of digoxin from pateints with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993: 329: 1.

    Article  PubMed  CAS  Google Scholar 

  40. Feldman MD, et al. Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in pateints with dilated cardiomyopathy. J Clin Invest 1988: 82: 1661.

    Article  PubMed  CAS  Google Scholar 

  41. Scwinger RHG, et al. Force-frequency-relation in human atrial and ventricular myocardium. Mol Cell Biochem 1993: 119: 73.

    Article  Google Scholar 

  42. Erdmann E. Digitalis-friend or foe? Eur Heart J 1995: 16: F16

    Article  Google Scholar 

  43. Ferguson DW, et al. Sympatho-inhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989: 80: 65.

    Article  PubMed  CAS  Google Scholar 

  44. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997: 336: 525.

    Article  Google Scholar 

  45. The Captopril-Digoxin Multicenter Reseach Group. Comparative effects of captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988: 259: 539.

    Article  Google Scholar 

  46. Cohn JN, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986: 314: 1547.

    Article  PubMed  CAS  Google Scholar 

  47. Agostoni PG, et al. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J 1986: 55: 391.

    Article  PubMed  CAS  Google Scholar 

  48. Packer M. Treatment of chronic heart failure. Lancet 1992: 340: 92.

    Article  PubMed  CAS  Google Scholar 

  49. Packer M. Vasodilator and inotropic drugs for chronic heart failure: Distinguishing hype from hope. Journal American College of Cardiology 1988: 12: 1299.

    Article  CAS  Google Scholar 

  50. Packer M, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. New England Journal of Medicine 1987: 317: 799.

    Article  PubMed  CAS  Google Scholar 

  51. Cohn JN, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991: 325: 303.

    Article  PubMed  CAS  Google Scholar 

  52. Packer M, et al. Effect of milrinone on mortality in severe chronic heart failure. N Engl J Med 1991: 325: 1468.

    Article  PubMed  CAS  Google Scholar 

  53. Packer M. Pathophysiologic mechanisms underlying the adverse effects of calcium channel blocking drugs in patients with chronic heart failure. Circulation 1989: 80(S. IV): 59.

    Google Scholar 

  54. The Stroke Prevention in Atrial Fibrillation Investigators. Stoke prevention in atrial fibrillation. Final results. Circulation 1991: 84: 527.

    Article  Google Scholar 

  55. Alderman EL, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983: 68: 785.

    Article  PubMed  CAS  Google Scholar 

  56. Higgins TL, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients: A clinical severity score. JAMA 1992: 267: 2344.

    Article  PubMed  CAS  Google Scholar 

  57. Englemeier RS, et al. Improvement in symptoms and exercise tolerence by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985: 72: 536.

    Article  Google Scholar 

  58. Waagstein F, et al. Beta-Blockers in cardiomyopathies: They work. Eur Heart J 1983: 4: 173.

    Article  PubMed  Google Scholar 

  59. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993: 71: C12.

    Article  Google Scholar 

  60. Gilbert EM, et al. Long-term beta-blocker vasodilator theray impoves cardiac function in idiopathic dialated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990: 88: 223.

    Article  PubMed  CAS  Google Scholar 

  61. Feuerstein GZ, Ruffolo Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995: 16: F38.

    Article  Google Scholar 

  62. Yue TL, et al. Carvedilol, a new beta-adrenergic antagonist and vasodilator antihypertensive drug, inhibits superpoxide release from human neutrophils. Eur J Pharmacol 1992: 214: 277.

    Article  PubMed  CAS  Google Scholar 

  63. Yue TL, et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exper Ther 1992: June: 92.

    Google Scholar 

  64. Raftery EB. Vasodilating beta-blockers in heart failure. Eur Heart J 1995: 16: F32.

    Article  Google Scholar 

  65. Packer M. Long-term stategies in the management of heart failure: Looking beyond ventricular function and symptoms. Am J Cardiol 1992: 69: G150.

    Article  Google Scholar 

  66. Olsen SL, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995: 25: 1225.

    Article  PubMed  CAS  Google Scholar 

  67. Dickstein K, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performace in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995: 26: 438.

    Article  PubMed  CAS  Google Scholar 

  68. Binkley PF, et al. Flosequinan augements parasympathetic tone and attenuates sympathetic drive in congestive heart failure demonstration by analysis of heart rate variability. J Am Coll Cardiol 1992: 19: 147A.

    Google Scholar 

  69. Feldman AM, et al for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993: 329: 149.

    Article  PubMed  CAS  Google Scholar 

  70. Matsumori A, et al. Vesnarinoe, an inotropic agent, inhibits cytokine production by stimualted human blood from patients with heart failure. Circulation 1994: 89: 955.

    Article  PubMed  CAS  Google Scholar 

  71. Northridge DB, et al. Inhibition of the metabolism of atrial natriuretic factor cause diuresis and natriuresis in chronic heart failure. Am J Hypert 1990: 3: 682.

    CAS  Google Scholar 

  72. Neuberg GW, et al. Hemodynamic effects of renin inhibtion by enalkiren in chronic congestive heart failure. Am J Cardiol 1991: 67: 63.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daniel K. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Dangas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Gorlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Levy, D.K., Dangas, G., Gorlin, R. (1999). Pathophysiology and Management of Heart Failure. In: Contemporary Concepts in Cardiology. Developments in Cardiovascular Medicine, vol 217. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5007-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5007-5_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7274-5

  • Online ISBN: 978-1-4615-5007-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation